- Home
- MNOV
MNOV
Medicinova Inc
as 11-15-2024 4:00pm EST
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | 87.3M | IPO Year: | 2005 |
| Target Price: | N/A | AVG Volume (30 days): | 136.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.12 - $2.55 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Medicinova Inc News
MNOV Breaking Stock News: Dive into MNOV Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
Associated Press Finance
4 days ago
MediciNova: Q3 Earnings Snapshot
Simply Wall St.
4 days ago
3 US Penny Stocks With Market Caps Over $40M To Consider
GlobeNewswire
6 days ago
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
MT Newswires
24 days ago
Top Premarket Gainers
GlobeNewswire
25 days ago
MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)
Simply Wall St.
a month ago
MediciNova (NASDAQ:MNOV) shareholders have endured a 73% loss from investing in the stock five years ago
GlobeNewswire
2 months ago
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
Compare MNOV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MNOV Medicinova Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.